Rollins Financial’s AbbVie ABBV Stock Holding History

Rollins Financial’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,446	Closed	-$234K	–	113
2022 Q1	$234K	Buy	+1,446	New	+$210K	0.07%	107

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rollins Financial's ABBV Position: Q2 2022 in Review

Rollins Financial sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 1,446 shares — an estimated $234K sold.

Rollins Financial first reported a position in ABBV in Q1 2022 and held it in 1 quarter. The position peaked at $234K in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Rollins Financial reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Rollins Financial sold 1,446 AbbVie shares in Q2 2022, an estimated $234K.
Rollins Financial first reported a position in AbbVie in Q1 2022 and held it in 1 quarter.
Rollins Financial's AbbVie position peaked at $234K in Q1 2022.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Rollins Financial's 13F filing for Q2 2022, filed 8 Aug 2022.